Clinical trial
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
NCT02402062 is registered in ClinicalTrials.gov with Grupo Espanol de Tumores Neuroendocrinos as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
- Lead sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 11, 2015
- Completion date
- January 10, 2020
- Enrollment
- 17 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.